Usefulness of Robotic Stereotactic Assistance (ROSA®) Device for Stereoelectroencephalography Electrode Implantation: A Systematic Review and Meta-analysis

• Published in: Neurologia Medico-Chirurgica Vol. 64; no. 2; pp. 71 - 86
• Main Authors: KAEWBORISUTSAKUL, Anukoon, CHERNOV, Mikhail, YOKOSAKO, Suguru, KUBOTA, Yuichi
• Format: Journal Article
• Language: English; Japanese
• Published: Japan The Japan Neurosurgical Society 15.02.2024; THE JAPAN NEUROSURGICAL SOCIETY; Japan Science and Technology Agency
• Subjects: Convulsions & seizures; depth electrode implantation; Drug resistance; Drug Resistant Epilepsy - surgery; efficacy; Electrodes; Electrodes, Implanted; Electroencephalography - instrumentation; Epilepsy; Humans; Meta-analysis; Review; Robotic Stereotactic Assistance (ROSA®); robotic stereotactic assistance (rosaⓡ); Robotic Surgical Procedures - instrumentation; Seizures; stereoelectroencephalography; Stereotaxic Techniques; epilepsy; Robotic Stereotactic Assistance (ROSA®); stereoelectroencephalography; depth electrode implantation; efficacy
• ISSN: 0470-8105; 1349-8029
• DOI: 10.2176/jns-nmc.2023-0119

The aim of this study was to systematically review and meta-analyze the efficiency and safety of using the Robotic Stereotactic Assistance (ROSA®) device (Zimmer Biomet; Warsaw, IN, USA) for stereoelectroencephalography (SEEG) electrode implantation in patients with drug-resistant epilepsy. Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a literature search was carried out. Overall, 855 nonduplicate relevant articles were determined, and 15 of them were selected for analysis. The benefits of the ROSA® device use in terms of electrode placement accuracy, as well as operative time length, perioperative complications, and seizure outcomes, were evaluated. Studies that were included reported on a total of 11,257 SEEG electrode implantations. The limited number of comparative studies hindered the comprehensive evaluation of the electrode implantation accuracy. Compared with frame-based or navigation-assisted techniques, ROSA®-assisted SEEG electrode implantation provided significant benefits for reduction of both overall operative time (mean difference [MD], −63.45 min; 95% confidence interval [CI] from −88.73 to −38.17 min; P < 0.00001) and operative time per implanted electrode (MD, −8.79 min; 95% CI from −14.37 to −3.21 min; P = 0.002). No significant differences existed in perioperative complications and seizure outcomes after the application of the ROSA® device and other techniques for electrode implantation. To conclude, the available evidence shows that the ROSA® device is an effective and safe surgical tool for trajectory-guided SEEG electrode implantation in patients with drug-resistant epilepsy, offering benefits for saving operative time and neither increasing the risk of perioperative complications nor negatively impacting seizure outcomes.